FDA Law Blog: Biosimilars

DECEMBER 4, 2023

DEA has interpreted pharmacists’ corresponding responsibility as prohibiting the filling of a prescription where the pharmacist or pharmacy “knows or has reason to know” that the prescription is invalid. Holiday CVS, L.L.C. d/b/a CVS/Pharmacy, Nos. 219 and 5195; Decision and Order , 77 Fed. 62,316, 62,342 (Oct. Complaint ¶ 62.

Controlled Substances 139

Controlled Substances Documentation Dosage Prescription Filling 139

Putting Patients First Blog

JANUARY 27, 2025

However, the scope and complexity of the proposed rule may present implementation challenges. Standardized templates can help eliminate ambiguities, ensuring that all essential information is presented in an accessible and user-friendly manner.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Safe Biologics

MARCH 10, 2025

Small molecule drugs make up over 90% of prescriptions filled in the U.S. A recent survey of doctors who prescribe biosimilars found that only 11% of physicians believe all biosimilars should be deemed interchangeable. Ben Ray Lujn, D-New Mexico, has supported efforts to loosen biosimilar standards.

Biosimilars 130

Biosimilars Independent Pharmacies Drug Pricing Vaccines 130